Edition:
India

Evelo Biosciences Inc (EVLO.OQ)

EVLO.OQ on NASDAQ Stock Exchange Global Select Market

7.39USD
10:57pm IST
Change (% chg)

$0.37 (+5.27%)
Prev Close
$7.02
Open
$7.02
Day's High
$7.39
Day's Low
$7.02
Volume
993
Avg. Vol
9,645
52-wk High
$15.86
52-wk Low
$6.49

Latest Key Developments (Source: Significant Developments)

Evelo Biosciences Reports First Quarter 2019 Financial Results And Recent Business Highlights
Thursday, 2 May 2019 

May 2 (Reuters) - Evelo Biosciences Inc ::EVELO BIOSCIENCES REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS.Q1 LOSS PER SHARE $0.64.Q1 EARNINGS PER SHARE ESTIMATE $-0.52 -- REFINITIV IBES DATA.PLAN TO INTRODUCE NEW FORMULATION INTO ONGOING CLINICAL TRIALS IN SECOND HALF OF 2019.INITIAL CLINICAL DATA FOR EDP1066 EXPECTED EARLY IN Q3 OF 2019.ON TRACK TO DELIVER 10 CLINICAL READOUTS ACROSS 2019 AND 2020.EVELO BIOSCIENCES - EXPECTS CASH, CASH EQUIVALENTS, INVESTMENTS WILL ENABLE IT TO FUND PLANNED OPERATING EXPENSES & CAPEX REQUIREMENTS INTO H2 2020.  Full Article

Evelo Biosciences Qtrly Net Loss Per Share $0.49
Thursday, 14 Feb 2019 

Feb 14 (Reuters) - Evelo Biosciences Inc ::EVELO BIOSCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.EVELO BIOSCIENCES INC QTRLY NET LOSS PER SHARE - BASIC AND DILUTED $0.49.EVELO BIOSCIENCES INC - AS OF DECEMBER 31, 2018, CASH, CASH EQUIVALENTS AND INVESTMENTS WERE $147.9 MILLION.EVELO BIOSCIENCES INC - INITIAL CLINICAL DATA FOR EDP1066 IN ATOPIC DERMATITIS AND PSORIASIS EXPECTED IN 2Q 2019.EVELO BIOSCIENCES INC - INITIAL CLINICAL DATA FOR EDP1815 IN ATOPIC DERMATITIS AND PSORIASIS EXPECTED IN 2H 2019.  Full Article